Medicus Pharma director granted 50,000 stock options

Medicus Pharma Ltd. director Ajay Raju received a grant of stock options covering 50,000 common shares.

Rhea-AI Filing Summary

Medicus Pharma Ltd. director Ajay Raju received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and were granted as a compensation award at no upfront cost. They are scheduled to vest quarterly in four equal installments over one year, giving Raju the right, once vested, to buy Medicus Pharma common shares at the fixed exercise price until the options expire in 2031.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Raju Ajay

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 50,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

Key Figures

Options granted: 50,000 options Exercise price: $0.36 per share Underlying shares: 50,000 common shares +3 more

6 metrics

Options granted 50,000 options Stock option award to director Ajay Raju on June 3, 2026

Exercise price $0.36 per share Strike price for the 50,000 stock options

Underlying shares 50,000 common shares Shares issuable upon exercise of granted options

Expiration date June 3, 2031 Option term end for Ajay Raju’s grant

Vesting schedule 4 quarterly installments over 1 year Options vest in four equal quarterly tranches

Post-grant derivative holdings 50,000 options Total options held following this transaction

Key Terms

Stock Option (right to buy), exercise price, vest quarterly, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "0.3600" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest quarterly financial

"The option is scheduled to vest quarterly in four equal installments"

expiration date financial

"expiration_date: "2031-06-03T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Medicus Pharma (MDCX) report for Ajay Raju?

Medicus Pharma reported that director Ajay Raju received a grant of stock options for 50,000 common shares. These options were awarded at no upfront cost as part of his compensation and give him the right to buy shares at a fixed exercise price.

How many Medicus Pharma (MDCX) shares are covered by Ajay Raju’s new options?

The option grant to director Ajay Raju covers 50,000 underlying common shares of Medicus Pharma. Each option corresponds to one common share, providing potential future equity exposure if he chooses to exercise the options after they vest.

What is the exercise price of Ajay Raju’s Medicus Pharma (MDCX) stock options?

Ajay Raju’s stock options have an exercise price of $0.36 per Medicus Pharma common share. This fixed price allows him to purchase shares at $0.36 once the options vest and before they expire, regardless of the market price at that time.

When do Ajay Raju’s Medicus Pharma (MDCX) options vest and expire?

The options granted to Ajay Raju vest quarterly in four equal installments over one year from the June 3, 2026 grant date. They are scheduled to expire on June 3, 2031, giving him several years to exercise vested options.

Is Ajay Raju’s Medicus Pharma (MDCX) option grant a purchase or a compensation award?

The transaction is a compensation award, not an open-market purchase. The Form 4 classifies it as a grant or other acquisition, with 50,000 stock options awarded at no cost, providing the right to buy shares later at a $0.36 exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raju Ajay

(Last) (First) (Middle)

TWO LIBERTY PLACE

50 S. 16TH STREET, SUITE 2710

(Street)

PHILADELPHIA PENNSYLVANIA 19102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.36	06/03/2026		A		50,000		(1)	06/03/2031	Common Shares	50,000	$0	50,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Ajay Raju	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)